Notice of Results
March 25 2019 - 6:00AM
Summit Therapeutics plc (‘Summit’ or the
‘Company’)
Summit Therapeutics Provides Notice of Financial Results
for the Fourth Quarter and Fiscal Year Ended 31 January
2019
Oxford, UK, and Cambridge, MA, US, 25
March 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM:
SUMM), a leader in new mechanism antibiotic innovation, will
announce its financial results for the fourth quarter and fiscal
year ended 31 January 2019 on 27 March 2019.
Summit will host a conference call and webcast
the same day to discuss its operational progress at 12:00 noon GMT
/ 8:00am EDT. Conference call and webcast information will be
included in the full year results press release. A replay of the
call will also be available through the Company's website,
www.summitplc.com, shortly after its conclusion.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of
care for the benefit of patients, and create value for payors and
healthcare providers. We are currently developing new mechanism
antibiotics for C. difficile infection and gonorrhoea and are using
our proprietary Discuva Platform to expand our pipeline. For more
information, visit www.summitplc.com and follow us on Twitter
@summitplc.
Contacts
Summit |
|
|
Glyn
Edwards / Richard Pye (UK office) |
Tel: |
44
(0)1235 443 951 |
Michelle Avery (US office) |
|
+1
617 225 4455 |
|
|
|
Cairn Financial Advisers LLP (Nominated
Adviser) |
Tel: |
+44
(0)20 7213 0880 |
Liam
Murray / Tony Rawlinson |
|
|
|
|
|
N+1 Singer (Joint Broker) |
Tel: |
+44
(0)20 7496 3000 |
Aubrey Powell / Jen Boorer, Corporate FinanceTom Salvesen,
Corporate Broking |
|
|
|
|
|
Bryan Garnier & Co Limited (Joint Broker) |
Tel: |
+44
(0)20 7332 2500 |
Phil
Walker / Dominic Wilson |
|
|
MSL Group (US) |
Tel: |
+1
781 684 6557 |
Jon
Siegal |
|
summit@mslgroup.com |
|
|
|
Consilium Strategic Communications (UK) |
Tel: |
+44
(0)20 3709 5700 |
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / |
|
summit@consilium-comms.com |
Lindsey Neville |
|
|
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024